SCHEDULE 13G/A: Deep Track Capital Discloses 8.27% Stake in Context Therapeutics Inc.
Beneficial Ownership Disclosure
Deep Track Capital, LP, along with its affiliates, has disclosed a passive beneficial ownership of 8.27% in Context Therapeutics Inc., totaling 7,419,355 shares of common stock.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively beneficially own 7,419,355 shares of Context Therapeutics Inc. common stock.
- This ownership represents 8.27% of the company's outstanding common stock.
- The beneficial ownership is characterized by shared voting power and shared dispositive power over all 7,419,355 shares.
- The percentage of ownership is calculated based on 89,704,194 shares of common stock outstanding as of March 18, 2025, as reported in the issuer's 10-K filing on March 20, 2025.
- This filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously filed statement.
- The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Context Therapeutics Inc.
Sentiment
Score: 5
Explanation: The filing is a standard disclosure of passive beneficial ownership, providing factual information without indicating positive or negative operational or financial performance.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding the issuer's future performance or operations.
Industry Context
This filing is a standard disclosure of significant passive ownership by an investment firm in a publicly traded biotechnology company, common within the financial industry for transparency purposes.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can be viewed as a vote of confidence or simply a portfolio allocation.
Key Dates
| Date | Description |
|---|---|
| 03/18/2025 | Date as of which 89,704,194 Common Stock were outstanding, according to the issuer's 10-K. |
| 03/20/2025 | Date Context Therapeutics Inc. filed its 10-K with the SEC. |
| 03/31/2025 | Date of event which requires the filing of this statement. |
| 05/15/2025 | Date of filing and signature date for the Schedule 13G Amendment No. 1. |
Keywords
SEC filing, Schedule 13G, beneficial ownership, Context Therapeutics Inc., Deep Track Capital, common stock, institutional ownership, passive investment, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.